^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    luxdegalutamide (ARV-766)

    i
    Other names: ARV-766, ARV 766, ARV766, JSB 462, JSB462, JSB-462
    Associations

    News

    Trials
    Company:
    Arvinas, Novartis
    Drug class:
    Androgen receptor degrader, AR-V7 degrader
    Related drugs:
    Associations

    News

    Trials
    6d
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=130, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    1m
    CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
    P1/2, N=76, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    2ms
    CJSB462B12201: A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) (2024-520155-24-00)
    P1/2, N=46, Recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    2ms
    CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
    P1/2, N=76, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    3ms
    A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    luxdegalutamide (ARV-766)
    6ms
    An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
    P1/2, N=188, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    6ms
    An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
    P1/2, N=188, Not yet recruiting, Novartis Pharmaceuticals
    New P1/2 trial
    |
    tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    7ms
    A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    luxdegalutamide (ARV-766)
    9ms
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=130, Recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    10ms
    An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (clinicaltrials.gov)
    P2, N=150, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Xtandi (enzalutamide) • abiraterone acetate • luxdegalutamide (ARV-766)
    10ms
    An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    Xtandi (enzalutamide) • abiraterone acetate • luxdegalutamide (ARV-766)
    1year
    ARV-766-mCRPC-101: A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1/2, N=152, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=220 --> 152 | Trial completion date: Jun 2026 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    abiraterone acetate • luxdegalutamide (ARV-766)